CareDx Stock Rises Following American Society of Transplant Surgeons' Position Statement on Test Use
ASTS supports the use of dd-cfDNA as a biomarker of kidney transplant rejection, as well as peripheral blood gene expression profiling to help rule out heart transplant rejection.
MolDx Reimbursement Decision Likely to Have Negative Impact on CareDx, Natera Transplant Businesses
MolDx updated its guidance for rejection risk molecular testing with more restrictive language, potentially ending multimodal test coverage.
CareDx Q2 Revenues Grow 9 Percent but Miss Estimates as Firm Lowers Full-Year Guidance
Revenues rose 9 percent on test service growth, as the company’s net loss swelled to $21.7 million from $1.9 million in Q2 of last year.
GenDx Licenses cfDNA Assay for Rejection Monitoring From Medical College of Wisconsin
The method allows for less invasive and more economical post-transplant monitoring and could also be adapted for other organ applications.
CareDx Receives CE Mark for Hematopoietic Cell Transplantation Testing Kit, Analysis Software
The designation furthers the firm's expansion into the stem cell transplant space, which began with the launch of AlloCell in 2020.